Opendata, web and dolomites

SDS-OmiProbe SIGNED

Revolutionary opto-biological methodology for aggressive HER2 cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SDS-OmiProbe project word cloud

Explore the words cloud of the SDS-OmiProbe project. It provides you a very rough idea of what is the project "SDS-OmiProbe" about.

her2    subject    discordance    mortality    diagnostic    markers    fail    500    health    instant    tissue    die    revolutionary    drugs    rapid    cellular    realize    soa    gap    performed    billion    carries    concentration    tests    device    striking    clinical    disease    tool    biomarker    organization    cancers    million    efficacy    samples    cancer    according    optic    diagnosed    compelling    extracting    tools    report    business    close    morbidity    causes    detects    breast    tumours    levels    biopsies    world    realization    volume    market    marker    therapy    diagnosis    omiprobe    breakthrough       opportunity    opto    optimization    resolution    biopsy    single    projected    worldwide    global    transparency    tip    accuracy    probe    followed    companion    cell    cells    women    sds    methodology    essence    approximately    quantitative    expensive    worth    landscape    independent    14    trend    laboratory    vivo    trials    biological    annually    invasive   

Project "SDS-OmiProbe" data sheet

The following table provides information about the project.

Coordinator
SDS OPTIC SPOLKA AKCYJNA 

Organization address
address: KONSTANTYNOW 1F
city: LUBLIN
postcode: 20 708
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Poland [PL]
 Project website https://sdsoptic.pl/
 Total cost 3˙985˙000 €
 EC max contribution 3˙985˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SDS OPTIC SPOLKA AKCYJNA PL (LUBLIN) coordinator 3˙985˙000.00

Map

 Project objective

According to World Health Organization, cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases per year. Breast cancer is the most common cancer among women, and is considered the second most common cancer overall. Each year about 1.7 million new cases are diagnosed worldwide and over 500,000 women die from the disease.

Current diagnosis methods of cancers fail to deliver objective results. Diagnosis require extracting tissue samples via invasive and expensive biopsy, followed by laboratory analysis, which are subject to significant levels of discordance.

SDS Optic presents a revolutionary opto-biological methodology that allows for instant cellular processes studies including in-vivo cancer diagnosis with single-cell resolution. SDS-OmiProbe detects presence and measures concentration levels of the HER2 cancer cells in breast tumours. It is a breakthrough device that carries the potential to address the challenges of SoA cancer markers diagnosis and biopsies. In essence, it is a laboratory test at the tip of a probe, but with greater accuracy, efficacy and quantitative results. SDS-OmiProbe may also be used as a companion diagnostic tool for targeted therapy and targeted therapy drugs.

There is compelling evidence that our novel SDS-OmiProbe is addressing a rapid growth trend in a high volume market. Based on Transparency Market Research Report the OmiProbe target market of HER2- biomarker tests is projected to be worth $4.6 billion, with 7.5 million HER2 marker tests performed annually worldwide.

In order to close the striking gap in the landscape of currently available cancer diagnostic and targeted therapy tools, and to realize the significant global business opportunity the objective of this project is optimization of the SDS-OmiProbe device, followed by realization of independent clinical trials and dissemination of the results.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SDS-OMIPROBE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SDS-OMIPROBE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More